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The recent approval of vaccines and gene therapy products for human use produced in the 38 
Insect Cell-Baculovirus Expression Vector System (IC-BEVS) underlines the high potential and 39 
versatility of this platform. The interest in developing robust production processes emerges to 40 
cope with manufacturing pressure, as well as stringent product quality guidelines. Previously, 41 
we addressed the impact of the baculovirus infection on the physiology of insect host cell lines, 42 
identifying key cellular pathways enrolled in heterologous gene/protein expression. In the 43 
present work, this knowledge was applied to design tailored media supplementation schemes to 44 
boost IC-BEVS production yields and quality of enveloped viral particles: influenza VLPs (Inf-45 
VLP) and baculovirus vectors (BV).  46 
The addition of reduced glutathione, antioxidants and polyamines increased the cell 47 
specific yields of baculovirus particles up to 3 fold. Cholesterol was identified as the most 48 
critical system booster, capable of improving 2.5 and 6-fold cell specific yields of BV and Inf-49 
VLPs, respectively. Surprisingly, the combination of polyamines and cholesterol 50 
supplementation improved baculovirus stock quality, by preventing the accumulation of non-51 
infectious particles during viral replication while selectively increasing infectious particles 52 
production. In addition, the specific yields of both enveloped viral particles, BVs and Inf-VLPs, 53 
were also increased.  54 
The correlation between supplement addition and systems productivity was extensively 55 
analyzed, providing a critical assessment on final product quantity and quality as drivers of 56 
bioprocess optimization efforts. 57 
 58 
Key-words: Baculovirus-insect cell system; metabolism; productivity; product quality; 59 
bioprocess optimization; VLPs 60 
 61 
1. Introduction 62 
The insect cell-baculovirus expression system (IC-BEVS) is now on the frontline of both 63 
pharmaceutical and biotechnological fields after the recent approval of several human 64 
therapeutics produced in this system, namely Cervarix®, Flublok® and Glybera® (Cox and 65 
Hollister, 2009; Lowy and Schiller, 2006; Moran, 2012). As the market of IC-BEVS based 66 
biopharmaceuticals progresses (Lu et al., 2012; Ylä-Herttuala, 2012), the interest in developing 67 
high-titer and robust production processes is expected to rise.  68 
Molecular biology studies have provided exciting discoveries on baculovirus–host 69 
interactions (reviewed in Monteiro et al., 2012). However, the biological constraints that govern 70 
baculovirus infection in the biotechnological context are poorly understood. The analysis of cell 71 
culture parameters and media components influencing productivity has turned possible the 72 
implementation of high cell density bioprocesses with increased and sustained production of 73 
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recombinant proteins via BEVS (Bédard et al., 1997; Chan et al., 1998; Chiou et al., 2000). The 74 
combination of metabolic flux analysis with the rational design of a feeding strategy improved 75 
baculovirus yields (6- to 7-fold) in high cell density cultures (Carinhas et al., 2010). Also, the 76 
on-line monitoring of the oxygen uptake rate (OUR) in baculovirus infected insect cells 77 
supported the design of feeding strategies able to boost up to 13 times the recombinant protein 78 
yields (Palomares et al., 2004). Overall, the successful application of metabolic and bioprocess 79 
engineering strategies to the IC-BEVS shows that there is room for improvement. Also, it seems 80 
clear that knowledge on key parameters of cellular physiology can help in devising such efforts 81 
towards increased productivity. 82 
Although progress has been made in tuning the baculovirus to accommodate the expression 83 
of challenging targets (Bieniossek et al., 2012; Palmberger et al., 2013), the accumulation of 84 
defective interfering particles (DIF) with increasing viral passages constraints baculovirus-based 85 
bioprocesses (Pijlman et al., 2001). The loss of expression of heterologous gene(s) and low 86 
infectivity of the baculovirus expression vector occurs as a consequence of recombination 87 
events during viral replication (Pijlman et al., 2003), and the impact of the heterologous gene(s) 88 
on this event is not fully understood.  89 
In previous works, metabolic pathways correlated with baculovirus infection and IC-BEVS 90 
productivity were identified based on fluxome analysis (Bernal et al. 2009, Monteiro et al. in 91 
preparation) and metabolomic fingerprinting (Monteiro et al. 2014). Although several 92 
metabolic differences were assessed between the two insect cell lines more used for protein and 93 
virus production (Trichoplusia ni High Five and Spodoptera frugiperda Sf9 cells, respectively) 94 
responses to infection were very similar (Monteiro et al. 2014). 95 
In the present work, we designed culture supplementation schemes aiming to boost IC-96 
BEVS productivity and quality of complex enveloped viral particles: influenza VLPs (Inf-97 
VLPs) and baculovirus (BV). Supplements selection was based on our previous identification of 98 
the metabolic pathways correlated with IC-BEVS productivity (Monteiro et al., 2014), with the 99 
goal of enhancing pathway activity and systems performance. An orthogonal screening of 100 
culture conditions was performed to pin-point the culture setting leading to maximal 101 
productivity in Sf9 cells, addressing target specific key requirements. Finally, an optimized 102 
bioprocess for the production of high quality enveloped viral particles via BEVS was 103 
implemented.  104 
 105 
2. Materials and methods 106 
2.1.  Cell lines and culture maintenance 107 
Spodoptera frugiperda derived Sf9 cell line was obtained from the European Collection of 108 
Cell Cultures (No. 89070101, ECCAC). Cells were maintained in serum- and protein-free 109 
Sf900II insect cell culture medium (Gibco, Glasgow, UK) in 500 mL Erlenmeyer flasks 110 
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(Corning, USA) with 50 mL working volume. Cultures were kept in a humidified incubator 111 
operated at 90 rpm and 27ºC. Routinely, Sf9 cells were re-inoculated every 3-4 days at 0.45x106 112 
cells.mL-1. Cell concentration was determined by hemocytometer cell counts and viability 113 
evaluated by the trypan blue exclusion method. 114 
2.2. Baculoviruses and viral stock preparation 115 
The recombinant Autographa californica nucleopolyhedrovirus BvHA5M1 was used 116 
throughout the work as the expression vector of the enveloped influenza VLPs (Inf-VLPs). This 117 
vector is a dual baculovirus, encoding two influenza genes: Hemagglutinin type 5 (H5), under 118 
the control of the polyhedrin promoter, and matrix protein 1 (M1), under the control of the p10 119 
promoter.  120 
BvHA5M1 was amplified by infecting Sf9 cells at 1x106cells.mL-1 with a multiplicity of 121 
infection (MOI) of 0.01 IP.cell-1 in a 10 L bioreactor (ED10, Sartorius AG, Goettingen, 122 
Germany). To generate a highly concentrated viral stock, a polyethylene glycol (PEG)-based 123 
concentration process was applied. Briefly, virus-containing culture supernatant was mixed with 124 
8.5% (v/v) of a sterile PEG solution prepared in phosphate buffer saline (PBS), and incubated 125 
overnight at 4ºC. The mixture was centrifuged at 3200xg for 30 min at 4ºC, and the collected 126 
pellet containing the baculovirus was suspended in 0.5 M sucrose. The concentrated viral stocks 127 
were titrated, aliquoted and kept at -80ºC until further use.                128 
2.3. Baculovirus titration and total particles quantification 129 
Baculovirus infectious particles quantification was performed following the MTT assay, as 130 
previously described in Roldão et al. (2009). Baculovirus total particles concentration was 131 
assessed by counting the baculovirus particles in a Nanosight NS500 (Nanosight Ltd., Salisbury, 132 
UK), using the Nanoparticle Tracking Analysis (NTA) software. The average size of purified 133 
Inf-VLPs samples and baculovirus was identified a priori for the determination of the gates for 134 
both particles quantification (data not shown). To exclude minor errors due to counting of 135 
cellular debris, exosomes, and other particles that can interfere with the accuracy of the 136 
measurements, appropriate controls were performed (supernatant of non-infected cultures at the 137 
correspondent cell densities). The measurements were performed at least in triplicates with a 138 
typical standard deviation (SD) below 20%. 139 
2.4. Supplements preparation 140 
The culture supplements tested, listed in Table 1, were selected as boosters of the metabolic 141 
pathways correlated with IC-BEVS productivity. Supplements concentration was set taking into 142 
account the manufacturer instructions and preliminary assays of their impact in the specific 143 
productivity and viability of Sf9 cells (data not shown). Supplements were prepared in Sf900II 144 
insect culture media (Gibco), and stored according to the manufacturer instructions. Cholesterol 145 
supplementation was performed in combination with 0.4 mg.L-1 albumin (Merck Millipore, 146 
Billerica, MA, USA) as a carrier.  147 
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2.5. Cell growth, infection and production studies 148 
The experimental set-up is depicted in Figure 1. To identify the impact of the 149 
supplementation strategy on enveloped viral particles yields, an exploratory screening was 150 
designed using the Advanced Microscale Bioreactor (Ambr, model AMBR24c) culture system 151 
(TAP Biosystems, Cambridge, UK) (Fig. 1A) previously customized to be suitable for IC-152 
BEVS expression experiments (Berger et al., 2013a, 2013b). Importantly, a cooling element 153 
was installed to operate at the temperatures relevant for insect cell production (26-27ºC). The 154 
customized Ambr robot was placed in a tailor-made plastic containment for sterile operations. 155 
The oxygen was provided by compressed and filtered air, supplied by a tubing connected to the 156 
robot, avoiding costly pure air installation requirement. From the experimental design, 12 single 157 
use bioreactors without sparger tubings were inoculated manually with 13 mL of Sf9 cultures 158 
and the corresponding supplements (Fig 1). Sf9 cells were inoculated at 0.5x106 cells.mL-1, and 159 
infected at approximately 1x106 cells.mL-1 with MOIs of 0.2, 1 and 5 IP.cell-1. Each bioreactor 160 
was equipped with dissolved oxygen (DO) and pH sensors, automatically recording and 161 
monitoring each individual bioprocess. Culture agitation was performed by an 11.2 mm 162 
impeller, set at 1400 rpm. In order to provide sufficient oxygen to the cultures, an additional air 163 
input with a flowrate up to 0.9 mL/min was automatically provided to avoid the DO percentage 164 
to drop below 40%. In practice, the latter never dropped below 70%.  165 
To disclose specific requirements of each target in Sf9 host cell line, an extensive screening 166 
in 100 mL Erlenmeyers (Corning, USA), with 10 mL working volume, was performed (Fig. 167 
1B). Sf9 cells were inoculated at 0.5x106 cells.mL-1, kept at 27ºC and infected at 1x106 cells.mL-168 
1 with MOIs of 0.2, 1 and 5 IP.cell-1. Additionally, to evaluate if synergies between supplements 169 
would occur, the combination of culture supplements was performed at this same scale, using a 170 
MOI of 0.2 IP.cell-1(Fig. 1C).  171 
The best culture condition leading to higher cell specific productivities of enveloped viral 172 
particles was validated in a 0.5 L stirred tank bioreactor (BIOSTAT® QPlus, Sartorius AG, 173 
Goettingen, Germany) (Fig. 1D). DO was set to 30% of air saturation and controlled by 174 
sequential N2-stirring-O2 cascade mode with 0.01 vvm gas flow rate. Temperature was kept at 175 
27ºC and the operation was performed within a stirring range of 90-180 rpm. Sf9 cells were 176 
inoculated at 0.5x106 cells.mL-1 and infected with BvHA5M1 at an MOI of 0.2 IP.cell-1, 24 177 
hours after inoculation.  178 
For all culture settings (Fig. 1A-D), supplements were added in a two-times addition 179 
mode, at inoculation, in order to precondition cells enabling an adaptation phase to their 180 
addition, and at infection, to promote a productive cellular state, medium concentrations are 181 
detailed in Table 1. Non-supplemented cultures infected with the same set of MOIs were 182 
performed as controls. Samples were collected every 24 hours and cell concentration and 183 
viability assessed. To evaluate productivity, samples were collected at 48 hours post-infection 184 
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(hpi), the time after which the expression from polyhedrin and p10 promoters is maximal. In the 185 
bioreactor cultures, enveloped viral particles production was followed throughout the entire 186 
process (up to 96 hpi). 187 
2.6. Influenza VLPs quantification 188 
The quantification of the influenza VLPs (Inf-VLPs) was performed by solid phase 189 
sandwich ELISA (SEK002, Sino Biological Inc., Beijing, China) specific for the hemagglutinin 190 
(HA) displayed on the surface of the particles. The assay was done according to manufacturer 191 
instructions, and HA-containing particles quantified in culture supernatant samples. 192 
2.7. Product stability assays in supplemented media 193 
Samples of BVs in culture media were incubated with the supplements at the same 194 
concentration added to the cultures (Table 1). Stability assays were performed at 27ºC during 48 195 
hours, and supplement effect on baculovirus stability was evaluated by comparing virus 196 
infectivity before and after incubation. Appropriate controls were performed, subjected to the 197 
same incubation time in non-supplemented media. 198 
2.8. Statistical analysis 199 
Hypothesis testing was performed using Student’s t-test. A 95% confidence interval was 200 
considered to be statistically significant. 201 
 202 
3. Results 203 
3.1. Media manipulation strategies affect cell growth without compromising cell 204 
viability and product stability 205 
Ideally, medium supplements would improve cell productivity without compromising cell 206 
growth and product stability. The effect of culture supplements on the growth rate of Sf9 cells is 207 
presented in Table 2. GSH, antioxidants, polyamines and biotin significantly decreased the 208 
specific growth rate up to 2 fold, whereas cholesterol impaired cellular growth. Cell viability 209 
was not compromised by the supplement addition (data not shown) and baculovirus stability 210 
was not significantly affected (Supplementary fig. 1).  211 
3.2. Media manipulation strategies boost productivity of enveloped viral particles in 212 
Sf9 cells 213 
The exploratory screening using the Ambr culture system showed that baculovirus and Inf-214 
VLPs yields increased (Supplementary Figure 2) in Sf9 cells following supplementation. These 215 
results encouraged an extensive screening of the listed culture supplements (Table 1) and also 216 
the evaluation of the supplementation impact on product quality. 217 
The production of enveloped viral particles increased up to 3-fold by supplements with redox 218 
balancing properties, mainly GSH, antioxidants and polyamines (Fig. 2). Although this set of 219 
supplements decreased cell growth rate, their boost on cell specific productivity of infectious 220 
BVs was high enough to achieve higher volumetric productivities and cell specific yields when 221 
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compared to control cultures (Supplementary Table 1). Cholesterol supplementation boosted 222 
both BVs and Inf-VLPs cell specific yields by 2.5 and 6-fold, respectively (Fig. 2A and B), 223 
which is a noteworthy result given that cholesterol halted culture growth (Table 2). In general, 224 
higher improvements on BVs production were achieved in infections performed with medium-225 
high MOIs, yet for Inf-VLPs we could not trace a clear correlation between fold-change in the 226 
production and MOI used (Fig. 2).  227 
3.3. Media manipulation strategies improve the quality of baculovirus particles 228 
produced in Sf9 cells 229 
The baculovirus used throughout this work is a difficult to produce virus, since relatively low 230 
titers were reached upon virus stock preparation. Thus, this baculovirus is a good candidate to 231 
test our proof-of-principle and test whether these supplements could also affect product quality. 232 
To evaluate the effect of tested supplements on product quality we assessed the ratio of 233 
infectious (IPs) to total particles (TPs). Viral quality was defined as a direct measure of 234 
infectivity, meaning IPs generated. This analysis was performed in low MOIs infected cultures, 235 
since those conditions are recommended for virus amplification towards higher viral stock 236 
quality.  237 
Polyamines and cholesterol yielded proportional improvements of both TPs and IPs, 238 
resulting in similar TPs/IPs ratios (Fig. 3, upper panel). Importantly, GSH and antioxidants 239 
combined with polyamines supplementation increased the IPs levels without altering TPs 240 
formation (Fig. 3, bottom panel). Therefore, these supplements improved final stock quality, as 241 
demonstrated by the decrease in the TPs/IPs ratio (Fig. 3, upper panel). These results show that, 242 
in addition to productivity, final product quality is also enhanced with the tested supplements.  243 
3.4. Synergistic combination of supplements improve the production of enveloped 244 
viral particles in Sf9 cells 245 
The best supplements were combined in groups of metabolic related pathways, i.e.  oxidative 246 
stress and lipid metabolism and their impact on the specific productivity of Sf9 cells was 247 
evaluated. The correlation between MOI and supplements impact on productivity was not 248 
straightforward and depended on the target produced (Fig. 2). Since high MOI infections at 249 
larger scales can be limiting and we are working with a challenging virus regarding infectious 250 
particles titers, we decided to proceed with low MOI infections to analyze the synergies 251 
between the supplements. Infections were performed at low MOI and the production of BVs and 252 
Inf-VLPs assessed (Fig. 4). The combination of cholesterol with polyamines boosted the 253 
specific yields of BVs by 7-fold, twice the value obtained by the addition of cholesterol alone, 254 
while no beneficial effect was observed in the Inf-VLPs specific yields by adding up 255 
polyamines.  256 
3.5. Implementation of an optimal bioprocess for the production of enveloped viral 257 
particles in Sf9 cells via BEVS 258 
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The results obtained with cholesterol and polyamines supplementation were validated in 0.5 259 
L stirred-tank bioreactors (Fig. 5). The addition of both supplements increased the production of 260 
infectious BVs (Fig. 5A) and Inf-VLPs (Fig. 5B) compared to non-supplemented cultures. 261 
Additionally, virus quality was also improved since the ratio between TPs and IPs was lower in 262 
the supplemented cultures, and the virus amplification factor was enhanced by 6 fold (Table 3). 263 
 264 
4. Discussion 265 
Several reports on IC-BEVS bioprocess optimization describe fed-batch strategies to 266 
improve the production of recombinant proteins (Nguyen et al., 1993; Yang et al., 1996; Taticek 267 
and Shuler, 1997; Chan et al., 1998; Palomares et al., 2004) or non-enveloped viral vectors ( Liu 268 
et al., 2010; Mena et al., 2010). Even though the IC-BEVS is massively used for the production 269 
of VLPs (Liu et al., 2013), and efforts have been made in understanding which are the process 270 
parameters that contribute for better VLP yields (Cruz et al., 1998; Maranga et al., 2002; 271 
Palomares et al., 2012; Pillay et al., 2009; Vieira et al., 2005), reports on the identification of the 272 
metabolic constraints in such targets production are still scarce. This is especially critical in the 273 
case of enveloped viral particles produced via BEVS, challenging complex products with 274 
stringent quality requirements not yet fully understood. In the present work, we analyzed the 275 
impact of cell culture supplements in IC-BEVS productivity, focusing on enhancing quality and 276 
titers of enveloped viral particles. The rationale behind this approach was provided by our 277 
previous metabolomic characterization of the system, where metabolic pathways correlated with 278 
baculovirus replication and productivity were identified (Monteiro et al., 2014). The 279 
supplements tested were selected as boosters of these metabolic pathways, with the final goal of 280 
driving cellular performance towards a higher productivity phenotype. 281 
We observed that the addition of GSH, antioxidants and polyamines, increased cell specific 282 
yields of infectious baculovirus particles. Baculovirus stock quality, i.e. infectivity, is 283 
influenced by the metabolic state of the producer cell, as productivity and cellular metabolism 284 
are correlated (reviewed in Aucoin et al., 2010). Among several roles in a cell, GSH is involved 285 
in reactive oxygen species (ROS) detoxification and protein folding (Chakravarthi et al., 2006). 286 
Oxidative stress occurs as a consequence of baculovirus infection (Wang et al., 2001), which 287 
can be overcome by over-expressing the antioxidant enzyme manganese superoxide dismutase 288 
thus precluding lipid and protein oxidation in baculovirus infected cells (Wang et al., 2004). 289 
Besides aiding in nucleic acids stabilization and transcription modulation, polyamines are able 290 
to improve membrane rigidity, as well as preventing lipid peroxidation given their antioxidant 291 
properties (Wallace et al., 2003). The positive effect of polyamines on the production of 292 
enveloped virus has been described (Raina et al., 1981; Rodrigues et al., 2013). Replication of 293 
baculovirus vectors is susceptible to the cellular metabolic state (Carinhas et al., 2010, 2009), 294 
and as seen here can beneficiate from a less-oxidative cellular microenvironment. Thus, we 295 
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hypothesize that the joint action of polyamines and antioxidants, by empowering redox 296 
homeostasis, can contribute to the observed improvements on baculovirus yields with increased 297 
quality (i.e. infectivity). 298 
Although the recommended practices of baculovirus stock management were followed, such 299 
as viral amplification at low MOIs and maintenance of the virus working stock at low passage 300 
number (Lesch et al., 2011), only low-titer BvHA5M1 virus stocks were achieved. Several 301 
factors may explain this effect, like the recombinant construct expressed, which can influence 302 
the baculovirus stock titer either by promoting instability of the viral DNA or by being 303 
cytotoxic, for instance. We have seen that by simply expressing constructs of different variants 304 
of influenza hemagglutinin, the generated viral stocks have significantly different titers, with 10 305 
to 100 fold changes in infectious particles production (data not shown). A correlation between 306 
the expressed construct and the baculovirus titer appears to occur, and further work should be 307 
performed to disclose this effect. 308 
Cholesterol was the main system booster, capable of improving cell specific yields of both 309 
baculovirus and enveloped VLPs. The manipulation of lipid and cholesterol metabolism has 310 
culminated in improved production of enveloped viral particles in several producer systems 311 
(Cervera et al., 2013; Chen et al., 2010; Mitta et al., 2005; Rodrigues et al., 2009). Cholesterol 312 
has an important role in membrane fluidity and rigidity, being invaluable for biogenesis and 313 
functionality (Bloch, 1983), as well as aiding in the stabilization of viral particles envelope, 314 
maturation and budding (Chan et al., 2010), thus being a major contributor to viral infectivity. 315 
Although few works detail the role of lipids in the IC-BEVS, it is recognized that when insect 316 
cells are subjected to lipid deprivation cell degeneration occurs, and the production of 317 
baculovirus is impaired (Goodwin, 1991). Similarly to wild-type virus, the budding of 318 
influenza-derived VLPs from the host cell occurs preferentially at lipid rafts (Chen et al., 2007), 319 
i.e., bioactive domains in the plasma membrane enriched in cholesterol and sphingolipids 320 
(Simons and Ikonen, 1997). Evidences suggest that baculovirus budding is not restricted to such 321 
domains (Zhang et al., 2003), however, the importance of lipidic cytosolic vesicles trafficking 322 
during the baculovirus infection cycle was demonstrated (Long et al., 2006; Yuan et al., 2011). 323 
Supplementation with lipid components can not only influence host cell metabolism, by 324 
assisting lipid overproduction imposed during infection and production of enveloped viral 325 
particles, but also influence membrane biogenesis and homeostasis. Taken together, our 326 
observations highlight the importance of proper membrane fitness to enable correct folding of 327 
proteins that intimately interact with membrane lipids, and the budding of the viral particles thus 328 
produced in insect cells. 329 
Given the increasing popularity of the IC-BEVS as a vaccine production platform, the 330 
identification of key players in final product quantity and quality is pivotal. Identification of the 331 
traits that influence systems’ performance can empower us to develop cells with superior 332 
10 
 
phenotypes, improve target quality and implement more robust bioprocesses. For the IC-BEVS, 333 
the maintenance of redox homeostasis and an enhanced cholesterol metabolism are key 334 
parameters that should be considered when developing and implementing highly productive 335 
bioprocesses. The work herein presented merges fundamentals with applied research, which 336 
culminated in the implementation of an IC-BEVS bioprocess that delivers higher quality and 337 
quantity of enveloped viral particles. 338 
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List of Tables 480 
 481 
Table 1. List of culture medium supplements 482 
The supplements were added in a two times addition mode (at inoculation and upon infection). aConcentration of 483 
supplements added in each addition timing (inoculation and infection). 484 
 485 
Table 2. Effect of media supplements on Sf9 cell growth 486 
Supplement μa PDTb 
Control 0.030 ± 0.001 23 ± 1 
GSH 0.016** ± 0.001 43** ± 2 
Antioxidants 0.010** ± 0.003 69** ± 35 
Polyamines 0.008** ± 0.002 87 ± 20 
Antioxidants + Polyamines 0.014** ± 0.004 50 ± 22 
Taurine 0.020 ± 0.003 35 ± 6 
Nucleosides 0.029 ± 0.004 24 ± 3 
Biotin 0.016* ± 0.003 43 ± 7 
Lipids 0.027 ± 0.002 26 ± 2 
Cholesterol 0.000* ± 0.003 N.A. 
Units - aµ - Specific growth rate (h-1); bPDT - Population doubling time (h). 487 
The growth rate and PDT were calculated in the exponential phase of growth of non-infected cells after 24 hours 488 
incubation with the indicated supplements. Values are shown as average ± SD (n=3). N.A.- Not applicable. 489 
Statistical significance: *p value<0.05; **p value<0.01. 490 
 491 
 492 
Table 3. Summary of the effect of the supplementation strategy in bioreactor cultures on the 493 
final quality of the baculovirus stock produced. 494 
aThe amplification factor (AF) was calculated as the ratio between the volumetric productivity and the number of 495 
infectious baculovirus per mL at the time of infection (volumetric productivity/(CCI×MOI)). 496 
 497 
Supplement Abbreviation Stock concentration Concentration addeda Supplier Reference 
Antioxidants AOx 1000 x 1 x Sigma (Steinheim, Germany) A1345 
Biotin Bio 1 mM 10 µM Sigma B4639 
Cholesterol Chol 250 x 1 x Gibco (Glasgow, UK) 12531-018 
Lipids Lip 100 x 1 x Gibco  11905-031 
Nucleosides Nucl 100 x 1 x Merck Millipore  ES-008-D 
Polyamines Poly 1000 x 1 x Sigma  P8483 
Reduced glutathione GSH 100 mM  1 mM Sigma  G1404 
Taurine Tau 100 mM 10 mM Sigma T8691 
 Supplemented culture (Cholesterol+Polyamines) 
 Control culture (non-supplemented) 
Time (hpi) 3 24 48 72 96  3 24 48 72 96 
TP(102.cell-1) 0.8 ± 0.08 1.6 ± 0.2 3 ± 0.3 2.8 ± 0.28 4 ± 0.4  1.9 ± 0.2 2.6 ± 0.3 4.4 ± 0.4 5.2 ± 0.5 8.6 ± 0.7 
IP(10-1.cell-1) 0.8 ± 0.2 1.3 ± 0.4 3.2 ± 1 5.5 ± 2 6.9 ± 2  1.0 ± 0.3 0.8 ± 0.2 1.0 ± 0.3 1.6 ± 0.5 1.6 ± 0.5 
Ratio TP/IP 1.1x103 1.3x103 9.1x102 5.1x102 5.7x102  1.9x103 3.2x103 4.4x103 3.2x103 5.3x103 
AFa 7 18 69 128 124  10 7 8 21 26 
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List of Figure Captions: 498 
Figure 1. Schematic representation of the experimental workflow. The exploratory 499 
screening of culture supplements (A) was performed in the TAP Ambr system, the extensive 500 
screening (B) and the analysis of the synergistic effects (C) were performed in Erlenmeyers and 501 
the scale-up (D) in 0.5 L stirred tank bioreactors. The culture conditions are shown, including 502 
the MOIs used and the supplements added to cultures. Abbreviations: GSH, reduced 503 
glutathione; AOx, antioxidants; Poly, polyamines; Tau, taurine; Nucl, nucleosides; Bio, biotin; 504 
Lip, lipids; Chol, cholesterol.  505 
Figure 2. Extensive screening of cell culture supplements for target-oriented bioprocess 506 
optimization in Sf9 cells. (A) Infectious baculovirus particles (IPs), and (B) Influenza VLPs 507 
(Inf-VLPs). The results represent the specific yield of IPs and Inf-VLPs, on a per cell basis. 508 
Infections were performed at CCI of 1x106 cells.mL-1 varying the MOI as indicated in the 509 
bottom axes. The data shown correspond to 48 hpi; error bars indicate variability between two 510 
independent supplemented cultures and three independent control cultures. 511 
Figure 3. Effect of cell culture supplements on viral stock quality. Upper panel: Total to 512 
infectious particles content ratio (TP/IP). Bottom panel: Specific yields of total (black bars) and 513 
infectious (light grey bars) viral particles produced in Sf9 cells. The left axis represents the 514 
quantification of baculovirus TPs, and the right axis the quantification of baculovirus IPs. 515 
Infections were performed at a CCI of 1x106 cells.mL-1 with an MOI of 0.2 IP·cell-1. The data 516 
shown correspond to 48 hpi; error bars indicate variability between two independent 517 
supplemented cultures or three independent control cultures. 518 
Figure 4. Synergistic effect of cell culture supplements on the specific yields of baculovirus 519 
IPs and Inf-VLPs produced in Sf9 cells. Dark grey bars correspond to infectious baculovirus 520 
titers and light grey bars to Influenza VLPs specific productivities. The results are shown as 521 
fold-change on the specific yields of supplemented versus control (non-supplemented) cultures. 522 
Infections were performed at a CCI of 1x106 cells.mL-1 with an MOI of 0.2 IP·cell-1. The data 523 
shown correspond to 48 hpi; error bars assume 30% of inter-assay variability for infectious 524 
baculovirus and 10% for influenza VLPs quantification. Control cultures were performed in 525 
triplicates. N.C.- No change.  526 
Figure 5. Improved production and quality of enveloped viral particles in Sf9 cells: 527 
Validation of the best supplementation scheme in stirred-tank bioreactors. (A) Cell specific 528 
yields of infectious baculovirus in control (   ) and supplemented cultures (   ); (B) Cell Specific 529 
yields of Influenza VLPs in control (  ) and supplemented (  ) cultures. The results show the 530 
bioprocess timeline after infection. Cultures were performed in a Biostat bioreactor, as 531 
16 
 
described in the Materials and Methods section. Infections were performed at a CCI of 1x106 532 
cells.mL-1 with an MOI of 0.2 IP·cell-1. The supplementation scheme comprised the addition of 533 
a combination of polyamines and cholesterol at the times of inoculation and infection, as 534 
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Table 1. List of culture medium supplements 572 
The supplements were added in a two times addition mode (at inoculation and upon infection). aConcentration of 573 



































Supplement Abbreviation Stock concentration Concentration addeda Supplier Reference 
Antioxidants AOx 1000 x 1 x Sigma (Steinheim, Germany) A1345 
Biotin Bio 1 mM 10 µM Sigma B4639 
Cholesterol Chol 250 x 1 x Gibco (Glasgow, UK) 12531-018 
Lipids Lip 100 x 1 x Gibco  11905-031 
Nucleosides Nucl 100 x 1 x Merck Millipore  ES-008-D 
Polyamines Poly 1000 x 1 x Sigma  P8483 
Reduced glutathione GSH 100 mM  1 mM Sigma  G1404 
Taurine Tau 100 mM 10 mM Sigma T8691 
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Table 2. Effect of media supplements on Sf9 cell growth 609 
Supplement μa PDTb 
Control 0.030 ± 0.001 23 ± 1 
GSH 0.016** ± 0.001 43** ± 2 
Antioxidants 0.010** ± 0.003 69** ± 35 
Polyamines 0.008** ± 0.002 87 ± 20 
Antioxidants + Polyamines 0.014** ± 0.004 50 ± 22 
Taurine 0.020 ± 0.003 35 ± 6 
Nucleosides 0.029 ± 0.004 24 ± 3 
Biotin 0.016* ± 0.003 43 ± 7 
Lipids 0.027 ± 0.002 26 ± 2 
Cholesterol 0.000* ± 0.003 N.A. 
 610 
Units - aµ - Specific growth rate (h-1); bPDT - Population doubling time (h). 611 
The growth rate and PDT were calculated in the exponential phase of growth of non-infected cells after 24 hours 612 
incubation with the indicated supplements. Values are shown as average ± SD (n=3). N.A.- Not applicable. 613 






















Table 3. Summary of the effect of the supplementation strategy in bioreactor cultures on the 634 
final quality of the baculovirus stock produced. 635 
aThe amplification factor (AF) was calculated as the ratio between the volumetric productivity and the number of 636 






























 Supplemented culture (Cholesterol+Polyamines) 
 Control culture (non-supplemented) 
Time (hpi) 3 24 48 72 96  3 24 48 72 96 
TP(102.cell-1) 0.8 ± 0.08 1.6 ± 0.2 3 ± 0.3 2.8 ± 0.28 4 ± 0.4  1.9 ± 0.2 2.6 ± 0.3 4.4 ± 0.4 5.2 ± 0.5 8.6 ± 0.7 
IP(10-1.cell-1) 0.8 ± 0.2 1.3 ± 0.4 3.2 ± 1 5.5 ± 2 6.9 ± 2  1.0 ± 0.3 0.8 ± 0.2 1.0 ± 0.3 1.6 ± 0.5 1.6 ± 0.5 
Ratio TP/IP 1.1x103 1.3x103 9.1x102 5.1x102 5.7x102  1.9x103 3.2x103 4.4x103 3.2x103 5.3x103 
AFa 7 18 69 128 124  10 7 8 21 26 
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Supplementary Table 1. Impact of media supplements on the productivity of enveloped viral 772 
particles in Sf9 cells 773 
Supplement MOI Inf-VLP Volumetric titera Inf-VLP Yield
b BVs Volumetric titerc BVs Yield
d 
Control 
0.2 0.45 ± 0.06 0.40 ± 0.1 1.98 ± 0.75 1.78 ± 0.09 
1 0.99 ± 0.53 1.52 ± 0.6 2.90 ± 0.49 2.89 ± 0.14 
5 4.38 ± 0.59 4.52 ± 0.4 6.12 ± 0.62 5.69 ± 0.19 
GSH 
0.2 0.56 ± 0.02 0.63 ± 0.03 3.32 ± 0.00 3.70 ± 0.00 
1 1.01 ± 0.10 1.13 ± 0.11 4.44 ± 0.21 4.97 ± 0.24 
5 3.85 ± 0.53 4.39 ± 0.60 7.39 ± 0.54 8.43 ± 0.62 
Antioxidants 
0.2 0.59 ± 0.02 0.76 ± 0.03 2.67 ± 0.05 3.47 ± 0.07 
1 1.13 ± 0.11 1.42 ± 0.14 6.35 ± 2.31 7.97 ± 2.90 
5 5.11 ± 0.70 5.72 ± 0.78 7.52 ± 1.28 8.42 ± 1.43 
Polyamines 
0.2 0.57 ± 0.02 0.86 ± 0.04 3.65 ± 0.44 5.50 ± 0.66 
1 1.37 ± 0.14 1.64 ± 0.16 2.90 ± 0.47 3.48 ± 0.56 




0.2 0.52 ± 0.02 0.51 ± 0.02 4.80 ± 0.13 4.71 ± 0.13 
1 1.01 ± 0.10 1.04 ± 0.10 4.48 ± 0.50 4.65 ± 0.52 
5 4.47 ± 0.61 4.49 ± 0.61 16.99 ± 0.15 17.05 ± 0.15 
Taurine 
0.2 0.66 ± 0.03 0.65 ± 0.03 3.78 ± 0.62 3.72 ± 0.61 
1 2.89 ± 0.29 2.34 ± 0.23 4.68 ± 1.98 3.80 ± 1.60 
5 5.39 ± 0.74 5.33 ± 0.73 6.28 ± 1.34 6.21 ± 1.32 
Nucleosides 
0.2 0.50 ± 0.02 0.46 ± 0.02 2.38 ± 0.12 2.20 ± 0.11 
1 2.34 ± 0.23 2.27 ± 0.23 5.82 ± 0.61 5.63 ± 0.42 
5 5.28 ± 0.72 5.27 ± 0.72 8.42 ± 1.08 8.39 ± 1.07 
Biotin 
0.2 0.60 ± 0.03 0.59 ± 0.02 2.50 ± 0.47 2.44 ± 0.46 
1 2.67 ± 0.27 2.46 ± 0.25 5.89 ± 0.11 5.44 ± 0.11 
5 5.74 ± 0.79 5.76 ± 0.79 6.51 ± 0.46 6.53 ± 0.46 
Lipids 
0.2 0.45 ± 0.02 0.41 ± 0.02 3.57 ± 0.14 3.25 ± 0.12 
1 2.08 ± 0.21 1.62 ± 0.16 5.52 ± 0.50 4.30 ± 0.39 
5 4.02 ± 0.55 3.73 ± 0.51 6.36 ± 1.73 5.91 ± 1.61 
Cholesterol 
0.2 0.53 ± 0.02 1.67 ± 0.07 4.35 ± 2.60 8.29 ± 1.64 
1 2.86 ± 0.29 7.95 ± 0.79 2.18 ± 0.61 6.06 ± 1.69 
5 12.16 ± 1.67 28.73 ± 3.94 4.37 ± 0.64 10.33 ± 1.52 
Units - angHA.mL-1; bngHA.10-6cells; c106IPs.mL-1; dIPs.cell-1. 774 
Values represent the mean average and variability of two independent replicates; samples were collected at 48 hpi and 775 









Supplementary Figure 1. Stability of infectious baculovirus in the presence of media 783 
supplements. Titers were normalized by the control (non-supplemented baculovirus sample) 784 





Supplementary Figure 2. Preliminary screening of the impact of culture supplements on the 788 
specific yields of Sf9 cells. (A) Infectious baculovirus, BVs (grey bars); (B) Influenza VLPs, 789 
Inf-VLPs (white bars). The results are presented as fold-change in the specific yields of 790 
supplemented versus control (non-supplemented) cultures. Dots indicate the fold-change in the 791 
volumetric titers of the target products analyzed. Cultures were performed in the Ambr system, 792 
as described in the M&M section. Infections were performed at a CCI of 1x106 cells.mL-1 793 
varying the MOI as indicated. The data corresponds to 48 hpi; error bars correspond to 30% of 794 
inter-assay variability for infectious BVs and 10% for Inf-VLPs quantification. Error bars for 795 
volumetric titers were ommitted for simplicity reasons. N.C. - No change. 796 
 797 
